• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Flecainide and atrial fibrillation cardioversion: what solutions at present and in the near future?

作者信息

Vitolo Marco, Mei Davide Antonio, Boriani Giuseppe

机构信息

Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena 41125, Italy.

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

Europace. 2025 Mar 28;27(4). doi: 10.1093/europace/euaf063.

DOI:10.1093/europace/euaf063
PMID:40165417
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11992564/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f1/11992564/e4e1257ffbf2/euaf063f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f1/11992564/e4e1257ffbf2/euaf063f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f1/11992564/e4e1257ffbf2/euaf063f1.jpg

相似文献

1
Flecainide and atrial fibrillation cardioversion: what solutions at present and in the near future?氟卡尼与心房颤动复律：目前及近期有哪些解决方案？
Europace. 2025 Mar 28;27(4). doi: 10.1093/europace/euaf063.
2
Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.静脉注射维纳卡兰与静脉注射氟卡尼在近期发作心房颤动转复中的比较。
Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):114-120. doi: 10.1177/2048872617728558. Epub 2017 Aug 29.
3
Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.氟卡尼在房颤经静脉内心脏复律中的有利作用。
J Am Coll Cardiol. 1999 Feb;33(2):333-41. doi: 10.1016/s0735-1097(98)00577-4.
4
Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED).冠心病患者急诊科房颤转复中氟卡尼与胺碘酮安全性和有效性对比的随机对照临床试验的原理与设计（FLECA-ED）
J Clin Med. 2023 Jun 10;12(12):3961. doi: 10.3390/jcm12123961.
5
Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?在持续性心房颤动电复律后，氟卡尼是否会恢复其抗心律失常活性？
Heart Rhythm. 2005 Mar;2(3):223-30. doi: 10.1016/j.hrthm.2004.11.014.
6
Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation.左心房组织速度成像可预测急性心房颤动患者对氟卡尼的反应。
Heart Rhythm. 2014 Mar;11(3):478-84. doi: 10.1016/j.hrthm.2013.12.010. Epub 2013 Dec 7.
7
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.电复律后短期与长期抗心律失常药物治疗心房颤动（Flec-SL）：一项前瞻性、随机、开放标签、盲终点评估试验。
Lancet. 2012 Jul 21;380(9838):238-46. doi: 10.1016/S0140-6736(12)60570-4. Epub 2012 Jun 18.
8
Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.氟卡尼用于心血管风险升高和持续性心房颤动患者的心脏复律：一项前瞻性观察研究。
Clin Res Cardiol. 2010 Jun;99(6):369-73. doi: 10.1007/s00392-010-0129-7. Epub 2010 Feb 24.
9
Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.在山羊持续性心房颤动的4个月期间，使用Ic类药物进行系列心脏复律。
J Cardiovasc Electrophysiol. 2006 Jun;17(6):648-54. doi: 10.1111/j.1540-8167.2006.00407.x.
10
Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide.基础 NT-proBNP 水平可预测氟卡尼转复心房颤动的成功率。
Neth Heart J. 2015 Mar;23(3):182-9. doi: 10.1007/s12471-015-0659-8.

本文引用的文献

1
Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.醋酸氟卡尼吸入溶液用于近期发作的有症状心房颤动的复律：3期RESTORE-1试验结果
Europace. 2025 Mar 28;27(4). doi: 10.1093/europace/euaf064.
2
Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.聚焦2024年欧洲心脏病学会/欧洲心胸外科学会心房颤动管理指南：10个新的关键方面。
Europace. 2024 Dec 3;26(12). doi: 10.1093/europace/euae298.
3
Sex- and age-specific differences in the use of antiarrhythmic therapies among atrial fibrillation patients: a nationwide cohort study.
在房颤患者中，抗心律失常治疗的性别和年龄特异性差异：一项全国性队列研究。
Europace. 2024 Oct 3;26(10). doi: 10.1093/europace/euae264.
4
Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021.全球 1990 年至 2021 年房颤/房扑的负担及其归因风险因素。
Europace. 2024 Jul 2;26(7). doi: 10.1093/europace/euae195.
5
Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry.房颤患者的症状和心血管疾病事件的健康相关生活质量和医疗保健成本：EURObservational Research Programme on Atrial Fibrillation 一般长期注册中心 27 个国家的纵向分析。
Europace. 2024 Jun 3;26(6). doi: 10.1093/europace/euae146.
6
Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial.长期钠通道阻滞剂治疗早期节律控制的安全性和有效性：EAST-AFNET 4 试验。
Europace. 2024 Jun 3;26(6). doi: 10.1093/europace/euae121.
7
Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial.口吸入氟卡尼治疗心房颤动转为窦性节律：INSTANT 阶段 2 试验。
JACC Clin Electrophysiol. 2024 Jun;10(6):1021-1033. doi: 10.1016/j.jacep.2024.02.021. Epub 2024 Apr 10.
8
Current management of atrial fibrillation in routine practice according to the last ESC guidelines: an EHRA physician survey-how are we dealing with controversial approaches?根据最新的 ESC 指南，常规实践中房颤的当前管理：EHRA 医师调查-我们如何处理有争议的方法？
Europace. 2024 Feb 1;26(2). doi: 10.1093/europace/euae012.
9
Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal.心房颤动与卒中预防：《欧洲心脏杂志》 25 年研究成果
Europace. 2023 Aug 2;25(9). doi: 10.1093/europace/euad226.
10
Recent Advances in Antiarrhythmic Drug Therapy.抗心律失常药物治疗的最新进展。
Drugs. 2023 Sep;83(13):1147-1160. doi: 10.1007/s40265-023-01923-3. Epub 2023 Aug 4.